Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive breast cancer [RPPA-Shortterm-BT474]

ABSTRACT: EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.

ORGANISM(S): Homo sapiens

PROVIDER: GSE50104 | GEO | 2014/08/13

SECONDARY ACCESSION(S): PRJNA216094

REPOSITORIES: GEO